The deal, valued at €158 million, includes 13 established branded generic products with a presence across more than 55 countries spanning Europe, the Middle East and Africa.
The transaction is expected to be completed by December 2026.
The acquired portfolio reported net sales of around €62 million in FY25, compared to €67 million in FY24 and €66 million in FY23.
As part of the agreement, GTBL will take over marketing authorisations, brands, regulatory dossiers, inventory and related commercial rights.
However, the acquisition does not include any manufacturing facilities, legal entities or employees, making it a capital-efficient and asset-light expansion.
The company said the acquisition marks a key step in its strategy to strengthen its global generics platform and expand its footprint in the anti-infective segment.
It will also provide immediate access to regulated and semi-regulated markets, enhancing GTBL’s international presence.
Additionally, the deal offers scope for forward integration, allowing the company to leverage its existing capabilities in fermentation-based intermediates and active pharmaceutical ingredients (APIs) to support the acquired finished dosage portfolio and improve value realisation across the chain.
Shares of Gujarat Themis Biosyn Ltd. ended 1.50% lower on Thursday at ₹323.10. The stock is down 27% so far this year.
First Published: Apr 24, 2026 6:48 AM IST
